EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 327 filers reported holding EXELIXIS INC in Q4 2021. The put-call ratio across all filers is 1.44 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $8,311,181 | +19.2% | 369,879 | +25.8% | 0.00% | 0.0% |
Q1 2024 | $6,975,148 | +123.8% | 293,938 | +126.2% | 0.00% | 0.0% |
Q4 2023 | $3,117,140 | +37.3% | 129,935 | +25.1% | 0.00% | – |
Q3 2023 | $2,269,909 | +10.1% | 103,886 | -3.7% | 0.00% | – |
Q2 2023 | $2,060,765 | +20.9% | 107,837 | +22.8% | 0.00% | – |
Q1 2023 | $1,703,907 | +51.8% | 87,785 | +25.4% | 0.00% | – |
Q4 2022 | $1,122,672 | +153.4% | 69,992 | +147.9% | 0.00% | – |
Q3 2022 | $443,000 | -11.8% | 28,233 | +19.0% | 0.00% | – |
Q3 2021 | $502,000 | -83.5% | 23,722 | -80.9% | 0.00% | -100.0% |
Q3 2020 | $3,035,000 | +235.0% | 124,120 | +141.5% | 0.00% | – |
Q4 2019 | $906,000 | -36.6% | 51,396 | -20.3% | 0.00% | – |
Q1 2018 | $1,428,000 | -78.1% | 64,478 | -69.9% | 0.00% | -100.0% |
Q4 2017 | $6,518,000 | -2.2% | 214,403 | -22.0% | 0.00% | -50.0% |
Q3 2017 | $6,664,000 | -19.4% | 275,034 | -18.1% | 0.00% | 0.0% |
Q2 2017 | $8,271,000 | -49.7% | 335,794 | -55.7% | 0.00% | -50.0% |
Q1 2017 | $16,443,000 | -5.1% | 758,799 | -34.7% | 0.00% | 0.0% |
Q4 2016 | $17,323,000 | -13.9% | 1,161,755 | -26.1% | 0.00% | -20.0% |
Q3 2016 | $20,116,000 | +115.1% | 1,572,745 | +31.3% | 0.01% | +150.0% |
Q2 2016 | $9,354,000 | +373.6% | 1,197,671 | +142.6% | 0.00% | +100.0% |
Q1 2016 | $1,975,000 | -64.1% | 493,759 | -49.4% | 0.00% | 0.0% |
Q4 2015 | $5,509,000 | +5.7% | 976,687 | +5.1% | 0.00% | 0.0% |
Q3 2015 | $5,214,000 | +47.6% | 929,403 | -1.0% | 0.00% | 0.0% |
Q2 2015 | $3,532,000 | +35.7% | 939,263 | -7.2% | 0.00% | 0.0% |
Q1 2015 | $2,602,000 | +45.0% | 1,012,323 | -18.8% | 0.00% | – |
Q4 2014 | $1,795,000 | -81.6% | 1,246,283 | -80.5% | 0.00% | -100.0% |
Q3 2014 | $9,773,000 | -82.2% | 6,387,863 | -60.7% | 0.00% | -80.0% |
Q2 2014 | $55,057,000 | -25.1% | 16,240,816 | -21.7% | 0.02% | -25.0% |
Q1 2014 | $73,466,000 | -46.7% | 20,752,832 | -7.6% | 0.02% | -50.0% |
Q4 2013 | $137,717,000 | +6.7% | 22,466,259 | +1.3% | 0.04% | 0.0% |
Q3 2013 | $129,013,000 | +37.1% | 22,167,222 | +7.0% | 0.04% | +29.0% |
Q2 2013 | $94,095,000 | – | 20,725,632 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |